PMID- 31765922
OWN - NLM
STAT- MEDLINE
DCOM- 20210319
LR  - 20210319
IS  - 1878-5883 (Electronic)
IS  - 0022-510X (Linking)
VI  - 408
DP  - 2020 Jan 15
TI  - Immunoglobulin administration for the treatment of CIDP: IVIG or SCIG?
PG  - 116497
LID - S0022-510X(19)30429-0 [pii]
LID - 10.1016/j.jns.2019.116497 [doi]
AB  - Chronic inflammatory demyelinating polyneuropathy (CIDP) is an acquired 
      neurological disorder characterized clinically by weakness and impaired sensory 
      function evolving over 2 months or more, loss or significant decrease in deep 
      tendon reflexes, and by electrophysiological evidence of peripheral nerve 
      demyelination. Expeditious diagnosis and treatment of CIDP early in the disease 
      course is critical such that irreversible disability can be avoided. Intravenous 
      immunoglobulin (IVIG) is one first-line and maintenance therapy option for CIDP. 
      The US Food & Drug Administration's (FDA's) approval of subcutaneous 
      immunoglobulin (SCIG) in 2018 provides patients with CIDP more treatment options 
      for maintenance therapy. The different options for administration of IG treatment 
      create the need for information to assist clinicians and patients in choosing the 
      optimal therapeutic approach. Considerations for pharmacokinetics, administration 
      procedures, adverse events, patient variables, and cost will all be discussed in 
      this article.
CI  - Copyright (c) 2019 The Authors. Published by Elsevier B.V. All rights reserved.
FAU - Allen, Jeffrey A
AU  - Allen JA
AD  - Department of Neurology, Division of Neuromuscular Medicine, University of 
      Minnesota, 516 Delaware Street SE, 12-150 PWB, Minneapolis, MN 55455, United 
      States of America. Electronic address: jaallen@umn.edu.
FAU - Gelinas, Deborah F
AU  - Gelinas DF
AD  - Department of Medical Affairs, Grifols Shared Services of North America, Inc., 79 
      TW Alexander Drive, Research Triangle Park, NC 27709, United States of America.
FAU - Freimer, Miriam
AU  - Freimer M
AD  - Department of Neurology, College of Medicine, Center for Neuromuscular Disorders, 
      Ohio State University, 395 W 12th Avenue, 7th Floor, Columbus, OH 43210, United 
      States of America.
FAU - Runken, M Chris
AU  - Runken MC
AD  - Global HEOR, Grifols Shared Services of North America, Inc., 79 TW Alexander 
      Drive, Research Triangle Park, NC 27709, United States of America.
FAU - Wolfe, Gil I
AU  - Wolfe GI
AD  - Department of Neurology, Jacobs School of Medicine and Biomedical Sciences, 
      University at Buffalo, SUNY, 1010 Main Street, 2nd Floor, Buffalo, NY 14202, 
      United States of America.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20191109
PL  - Netherlands
TA  - J Neurol Sci
JT  - Journal of the neurological sciences
JID - 0375403
RN  - 0 (Immunoglobulins, Intravenous)
SB  - IM
MH  - Humans
MH  - Immunoglobulins, Intravenous/*administration & dosage/pharmacokinetics
MH  - Infusions, Subcutaneous/*methods
MH  - Injections, Subcutaneous
MH  - Polyradiculoneuropathy, Chronic Inflammatory Demyelinating/diagnosis/*drug 
      therapy/metabolism
MH  - Randomized Controlled Trials as Topic/*methods
OTO - NOTNLM
OT  - Chronic inflammatory demyelinating polyneuropathy
OT  - Intravenous immunoglobulin
OT  - Maintenance therapy
OT  - Route of administration comparison
OT  - Subcutaneous immunoglobulin
EDAT- 2019/11/26 06:00
MHDA- 2021/03/20 06:00
CRDT- 2019/11/26 06:00
PHST- 2019/05/30 00:00 [received]
PHST- 2019/08/20 00:00 [revised]
PHST- 2019/09/17 00:00 [accepted]
PHST- 2019/11/26 06:00 [pubmed]
PHST- 2021/03/20 06:00 [medline]
PHST- 2019/11/26 06:00 [entrez]
AID - S0022-510X(19)30429-0 [pii]
AID - 10.1016/j.jns.2019.116497 [doi]
PST - ppublish
SO  - J Neurol Sci. 2020 Jan 15;408:116497. doi: 10.1016/j.jns.2019.116497. Epub 2019 
      Nov 9.